# Lithuania Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Lithuania HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Lithuania (LTU)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $921.7M
- Products: 37
- Buyer markets: 30
- Average CAGR: +33.0%
- Global sector size: $763.3B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $310.3B | $198.5M | $116.4B | +18.4% | 22 | +0.1% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $166.8B | $59.9M | $69.3B | +66.7% | 17 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $30.7B | $13.2K | $34.5B | +66.2% | 5 | +0.0% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $19.4B | $49.1K | $23.0B | +29.2% | 3 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $30.5B | $17.0M | $17.3B | +72.2% | 7 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $23.1B | $45.0M | $17.2B | +38.8% | 8 | +0.1% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $16.3B | $23.7K | $16.8B | +6.7% | 3 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $26.0B | $9.0M | $15.9B | +29.4% | 8 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $15.0B | $1.1M | $14.4B | +31.0% | 5 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $10.1B | $29.9M | $8.5B | +28.3% | 3 | +0.2% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $13.4B | $38.8M | $8.5B | +38.3% | 3 | +0.2% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $5.5B | $1.8K | $7.1B | -2.7% | 2 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $16.8B | $2.7M | $7.0B | +13.3% | 3 | +0.0% |
| HS 300339 - Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | $3.4B | $986.8 | $6.7B | +49.2% | 1 | +0.0% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $4.7B | $5.6K | $6.1B | +2.4% | 3 | +0.0% |
| HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $6.1B | $133.8 | $5.9B | +12.8% | 2 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $374.1M | $5.8B | +42.6% | 3 | +2.2% |
| HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $6.8B | $9.9K | $5.0B | +2.3% | 2 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $587.3K | $4.1B | +15.5% | 2 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $4.5B | $4.3K | $3.8B | +73.8% | 2 | +0.0% |
| HS 310540 - Fertilizers, mineral or chemical: ammonium dihydrogenorthophosphate (monoammonium phosphate) and mixtures thereof with diammonium hydrogenorthophosphate (diammonium phosphate) | $3.9B | $2.6M | $2.9B | +11.1% | 2 | +0.0% |
| HS 285390 - Phosphides, chemically defined or not, not ferrophosphorus: other inorganic compounds n.e.c. (including distilled, conductivity water and water of like purity): liquid air, rare gases removed or not: compressed air: amalgams, not precious metal amalgams | $1.3B | $351.7K | $2.4B | +115.8% | 1 | +0.0% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $1.4B | $4.0K | $2.3B | +26.2% | 1 | +0.0% |
| HS 290531 - Alcohols: acyclic, diols: ethylene glycol (ethanediol) | $3.2B | $301.3 | $2.2B | -4.1% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $3.4K | $2.0B | -8.1% | 1 | +0.0% |
| HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $181.8K | $2.0B | +8.3% | 1 | +0.0% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $49.6 | $1.4B | -1.9% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $49.6K | $1.4B | +34.5% | 1 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $2.8B | $2.2K | $1.3B | +2.8% | 1 | +0.0% |
| HS 310221 - Fertilizers, mineral or chemical: nitrogenous, ammonium sulphate | $965.4M | $1.0M | $1.3B | +5.1% | 1 | +0.3% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $144.6 | $1.2B | -3.2% | 1 | +0.0% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $718.1M | $1.7K | $1.2B | -6.9% | 1 | +0.0% |
| HS 310530 - Fertilizers, mineral or chemical: diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $140.5M | $1.2B | +29.1% | 1 | +4.0% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $2.3B | $153.2K | $1.1B | +49.7% | 1 | +0.0% |
| HS 310559 - Fertilizers, mineral or chemical: containing the two fertilizing elements nitrogen and phosphorus, other than nitrates and phosphates | $581.7M | $128.0K | $1.1B | +26.5% | 1 | +0.0% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.2B | $15.4 | $1.1B | -53.4% | 1 | +0.0% |
| HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $24.7K | $1.1B | -31.5% | 1 | +0.1% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $113.6B calculated opportunity across 17 products.
- Germany (DEU): $38.6B calculated opportunity across 12 products.
- Switzerland, Liechtenstein (CHE): $37.8B calculated opportunity across 5 products.
- Slovenia (SVN): $37.7B calculated opportunity across 5 products.
- Belgium (BEL): $30.6B calculated opportunity across 6 products.
- China (CHN): $24.5B calculated opportunity across 9 products.
- Netherlands (NLD): $20.6B calculated opportunity across 6 products.
- United Kingdom (GBR): $12.3B calculated opportunity across 6 products.
- Italy (ITA): $12.1B calculated opportunity across 3 products.
- Spain (ESP): $10.3B calculated opportunity across 5 products.
- Japan (JPN): $9.6B calculated opportunity across 3 products.
- Canada (CAN): $9.1B calculated opportunity across 5 products.

## Growth stars

- HS 285390: +115.8% average CAGR, $2.4B calculated opportunity.
- HS 381512: +73.8% average CAGR, $3.8B calculated opportunity.
- HS 300212: +72.2% average CAGR, $17.3B calculated opportunity.
- HS 300215: +66.7% average CAGR, $69.3B calculated opportunity.
- HS 300214: +66.2% average CAGR, $34.5B calculated opportunity.
- HS 281820: +49.7% average CAGR, $1.1B calculated opportunity.
- HS 300339: +49.2% average CAGR, $6.7B calculated opportunity.
- HS 382200: +42.6% average CAGR, $5.8B calculated opportunity.
- HS 382499: +38.8% average CAGR, $17.2B calculated opportunity.
- HS 293499: +38.3% average CAGR, $8.5B calculated opportunity.

## Diversification opportunities

- HS 300490: 22 buyer markets, $116.4B calculated opportunity.
- HS 300215: 17 buyer markets, $69.3B calculated opportunity.
- HS 382499: 8 buyer markets, $17.2B calculated opportunity.
- HS 300439: 8 buyer markets, $15.9B calculated opportunity.
- HS 300212: 7 buyer markets, $17.3B calculated opportunity.
- HS 300214: 5 buyer markets, $34.5B calculated opportunity.
- HS 300220: 5 buyer markets, $14.4B calculated opportunity.
- HS 293359: 3 buyer markets, $23.0B calculated opportunity.
- HS 293399: 3 buyer markets, $16.8B calculated opportunity.
- HS 382600: 3 buyer markets, $8.5B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.